New Delhi: In a significant judgment of Bevatas vs Bevetex, reinforcing the importance of patient safety and trademark protection in the pharmaceutical sector, the Delhi High Court has permanently restrained Ahmedabad-based Intas Pharmaceuticals from manufacturing, marketing, or selling its cancer drug under the brand name “Bevatas.”

The Court held that the mark infringes upon Sun Pharma Laboratories’ registered trademark “Bevetex,” a drug used in the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.

Court’s Key Observations on Bevatas vs Bevetex

Justice Tejas Karia noted that:

• Sun Pharma is the prior and continuous user of the “Bevetex” mark since 1983, with commercial use dating back to 2015.
• The company holds statutory rights over the trademark, which remain protected.

Rejecting Intas Pharma’s defence, the Court ruled that:

• The marks “Bevatas” and “Bevetex” are structurally and phonetically similar
• There exists a high likelihood of confusion, especially for an average consumer with imperfect recollection

The Court emphasized:

“Confusion between drugs (Bevatas vs Bevetex) treating different ailments is even more dangerous, and therefore a strict approach shall be applied.”

Public Health Takes Priority

A major highlight of the judgment was its strong stance on patient safety. The Court clearly stated:

👉 Public health is of paramount importance, and there can be no leniency in matters involving potential drug confusion.

It further rejected Intas Pharma’s argument that:

• The drugs contain different molecules
• They are Schedule H (prescription-only) medicines

The Court observed that:

• Patients, attendants, and even pharmacists are not expected to differentiate drugs based on chemical composition
• The risk of confusion increases significantly when prescriptions are handled indirectly

Why This Case Matters

This ruling on Bevatas vs Bevetex is not just a trademark dispute—it sets a critical precedent in the pharmaceutical industry by highlighting the life-threatening consequences of brand name similarity.

Why Choosing a Unique Brand Name is Crucial in Pharma

Unlike other industries, branding in pharmaceuticals is not just about marketing—it is directly linked to patient safety and clinical outcomes.

1. Prevents Medication Errors

Even minor similarities eg. Bevatas vs Bevetex, in drug names can lead to:

• Wrong drug dispensing
• Incorrect administration
• Severe adverse reactions

In critical fields like oncology, such errors can be fatal.

2. Protects Public Health

Confusion between drug names can:

• Delay proper treatment
• Lead to ineffective therapy
• Increase healthcare complications

This is why courts apply a stricter standard in pharma trademark disputes.

3. Builds Trust and Credibility

A unique and distinct brand name:

• Enhances recognition among doctors and pharmacists
• Builds long-term trust
• Reduces ambiguity in prescriptions

4. Legal Protection & Compliance

Using a distinct brand name ensures:

• Strong trademark protection
• Avoidance of costly legal battles
• Compliance with regulatory guidelines

5. Global Standardization

With increasing globalization of pharmaceuticals:

• Unique names reduce confusion across countries
• Align with international drug safety norms

Conclusion

The Delhi High Court’s ruling on Bevatas vs Bevetex serves as a powerful reminder that in the pharmaceutical industry, a name is not just a brand—it is a matter of life and death.

By prioritizing patient safety over commercial interests, the judgment reinforces the urgent need for:

• Strict scrutiny in drug naming
• Responsible branding practices
• A patient-first approach in healthcare

For more details, follow us on X (Twitter), Instagram & Facebook. And our website MED COLLEGE DARSHAN.